Bone Fracture-Pipeline Review, H1 2015

Bone Fracture-Pipeline Review, H1 2015

  • Products Id :- GMDHC6622IDB
  • |
  • Pages: 80
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Bone Fracture-Pipeline Review, H1 2015


Global Markets Direct's, 'Bone Fracture-Pipeline Review, H1 2015', provides an overview of the Bone Fracture's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bone Fracture, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Fracture and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Bone Fracture

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Bone Fracture and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Bone Fracture products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Bone Fracture pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Bone Fracture

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Bone Fracture pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Bone Fracture Overview 9

Therapeutics Development 10

Pipeline Products for Bone Fracture-Overview 10

Pipeline Products for Bone Fracture-Comparative Analysis 11

Bone Fracture-Therapeutics under Development by Companies 12

Bone Fracture-Therapeutics under Investigation by Universities/Institutes 14

Bone Fracture-Pipeline Products Glance 15

Clinical Stage Products 15

Early Stage Products 16

Bone Fracture-Products under Development by Companies 17

Bone Fracture-Products under Investigation by Universities/Institutes 18

Bone Fracture-Companies Involved in Therapeutics Development 19

Arcarios BV 19

AstraZeneca PLC 20

Biogenomics Limited 21

Bone Therapeutics SA 22

Escape Therapeutics, Inc. 23

Juventas Therapeutics, Inc. 24

Kaken Pharmaceutical Co., Ltd. 25

Kolon Life Science, Inc. 26

Kuros Biosurgery AG 27

Laboratorios SALVAT S.A. 28

Novartis AG 29

OrgaNext Research BV 30

TissueGene, Inc. 31

Viking Therapeutics, Inc. 32

Bone Fracture-Therapeutics Assessment 33

Assessment by Monotherapy Products 33

Assessment by Combination Products 34

Assessment by Target 35

Assessment by Mechanism of Action 37

Assessment by Route of Administration 39

Assessment by Molecule Type 41

Drug Profiles 43

(nandrolone decanoate + cholecalciferol)-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

ALLOB-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

AZD-2858-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

bimagrumab-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

denosumab biosimilar-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

dibotermin alfa-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Gene Therapy for Bone Fracture-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

JVS-200-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

KCB-1B-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

KLS-Bfr-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

KUR-111-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

KUR-113-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

LWnt-3a-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

OsteoStem-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Recombinant Protein to Activate TNF alfa for Fracture Repair-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Stem Cell Therapy for Bone Regeneration-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Stromal Cell Therapy for Fracture Repair-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Synthetic Peptide for Osteoporosis and Bone Fracture-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

TG-B-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

VK-5211-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

Bone Fracture-Recent Pipeline Updates 69

Bone Fracture-Dormant Projects 72

Bone Fracture-Discontinued Products 73

Bone Fracture-Product Development Milestones 74

Featured News & Press Releases 74

Mar 23, 2015: Bone Therapeutics treats first patients in ALLOB Phase IIA spinal fusion trial 74

Jan 19, 2015: Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB Phase I/IIA Delayed-Union Trial 74

Dec 16, 2014: Bone Therapeutics Confirms Safety in ALLOB Phase I/IIa Trial for Delayed-Union Fractures 75

Oct 09, 2014: Bone Therapeutics extends ALLOB phase I/IIa trial to Germany 75

Jun 25, 2014: Bone Therapeutics Starts Patient Treatment in First Ever Clinical Trial with Allogeneic Bone Cell Therapy Product 76

Oct 01, 2013: Bone Therapeutics receives clearance for ALLOB phase I/IIa trial 77

Aug 29, 2013: Researcher Awarded $5 Million to Advance Future Stem Cell Treatments for Segmental Bone Fractures 77

Appendix 79

Methodology 79

Coverage 79

Secondary Research 79

Primary Research 79

Expert Panel Validation 79

Contact Us 79

Disclaimer 80

List of Tables

Number of Products under Development for Bone Fracture, H1 2015 10

Number of Products under Development for Bone Fracture-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Investigation by Universities/Institutes, H1 2015 18

Bone Fracture-Pipeline by Arcarios BV, H1 2015 19

Bone Fracture-Pipeline by AstraZeneca PLC, H1 2015 20

Bone Fracture-Pipeline by Biogenomics Limited, H1 2015 21

Bone Fracture-Pipeline by Bone Therapeutics SA, H1 2015 22

Bone Fracture-Pipeline by Escape Therapeutics, Inc., H1 2015 23

Bone Fracture-Pipeline by Juventas Therapeutics, Inc., H1 2015 24

Bone Fracture-Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2015 25

Bone Fracture-Pipeline by Kolon Life Science, Inc., H1 2015 26

Bone Fracture-Pipeline by Kuros Biosurgery AG, H1 2015 27

Bone Fracture-Pipeline by Laboratorios SALVAT S.A., H1 2015 28

Bone Fracture-Pipeline by Novartis AG, H1 2015 29

Bone Fracture-Pipeline by OrgaNext Research BV, H1 2015 30

Bone Fracture-Pipeline by TissueGene, Inc., H1 2015 31

Bone Fracture-Pipeline by Viking Therapeutics, Inc., H1 2015 32

Assessment by Monotherapy Products, H1 2015 33

Assessment by Combination Products, H1 2015 34

Number of Products by Stage and Target, H1 2015 36

Number of Products by Stage and Mechanism of Action, H1 2015 38

Number of Products by Stage and Route of Administration, H1 2015 40

Number of Products by Stage and Molecule Type, H1 2015 42

Bone Fracture Therapeutics-Recent Pipeline Updates, H1 2015 69

Bone Fracture-Dormant Projects, H1 2015 72

Bone Fracture-Discontinued Products, H1 2015 73

List of Figures

Number of Products under Development for Bone Fracture, H1 2015 10

Number of Products under Development for Bone Fracture-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 33

Number of Products by Top 10 Targets, H1 2015 35

Number of Products by Stage and Top 10 Targets, H1 2015 36

Number of Products by Top 10 Mechanism of Actions, H1 2015 37

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 38

Number of Products by Top 10 Routes of Administration, H1 2015 39

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 40

Number of Products by Top 10 Molecule Types, H1 2015 41

Number of Products by Stage and Top 10 Molecule Types, H1 2015 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Arcarios BV

AstraZeneca PLC

Biogenomics Limited

Bone Therapeutics SA

Escape Therapeutics, Inc.

Juventas Therapeutics, Inc.

Kaken Pharmaceutical Co., Ltd.

Kolon Life Science, Inc.

Kuros Biosurgery AG

Laboratorios SALVAT S.A.

Novartis AG

OrgaNext Research BV

TissueGene, Inc.

Viking Therapeutics, Inc.

Bone Fracture Therapeutic Products under Development, Key Players in Bone Fracture Therapeutics, Bone Fracture Pipeline Overview, Bone Fracture Pipeline, Bone Fracture Pipeline Assessment

select a license

Single User License
USD 2000 INR 129780
Site License
USD 4000 INR 259560
Corporate User License
USD 6000 INR 389340



The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]